✕
For Patients & Families
Our Science
Connect with Us
STAR-0310, a monoclonal antibody OX40 antagonist, is in development for the potential treatment of atopic dermatitis (AD). OX40 inhibition is a clinically validated mechanism for the treatment of AD.
Using half-life extension technology with the aim of durable efficacy with less frequent dosing every 2-3 months, STAR-0310 is designed with the potential to be a first-choice treatment that reduces disease and treatment burden to help normalize the lives of people with atopic dermatitis.
STAR-0310 has a potential best-in-class OX40 inhibitor profile: high affinity for competitive efficacy, potential for best-in-class safety and tolerability with low T cell depletion from ADCC or possible on-target cellular toxicity, and less frequent dosing.
We initiated a Phase 1a trial of STAR-0310 in healthy subjects in January of 2025, which is intended to assess the safety, tolerability, pharmacokinetics, and immunogenicity of STAR-0310. We expect early proof-of-concept results from the Phase 1a trial in the third quarter of 2025.
